Keros Therapeutics, Inc. - common stock (KROS)

The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence.

The company is continuing to test the lowest dose of its pulmonary arterial hypertension drug.

Keros Therapeutics halts high-dose cibotercept treatment in the TROPOS trial after safety concerns, with topline results anticipated in Q2 2025.

Takeda inks a licensing deal with Keros for elritercept, a late-stage anemia drug, and plans a Phase 3 trial in myelodysplastic syndromes.

Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86.

KROS stock results show that Keros Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Keros Therapeutics is advancing novel therapies for hematological and cardiopulmonary disorders via TGF-β signaling regulation. Oppenheimer rates KROS Outperform with a $102 price target.

KROS stock results show that Keros Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.<

U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. (NYSE: LW) rose during Thursday’s session following better-than-expected quarterly results.

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.